AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

13.430

-0.080-0.59%

Volume:280.47K

Turnover:3.73M

Market Cap:1.70B

PE:11.70

High:13.655

Open:13.600

Low:13.100

Close:13.510

52wk High:22.985

52wk Low:8.610

Shares:126.64M

Float Shares:108.39M

Volume Ratio:0.39

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.148

EPS(LYR):1.086

ROE:54.96%

ROA:41.13%

PB:5.26

PE(LYR):12.37

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-4.91%

Capital Flow

Inflow:

Outflow:

News

Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program

MT Newswires Live

Neuren Pharmaceuticals - Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back

THOMSON REUTERS

Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies

MT Newswires Live

BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NEU.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":13.43,"timestamp":1770786720000,"preClose":13.51,"halted":0,"volume":280467,"delay":0,"changeRate":-0.005921539600296082,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":1.147709,"marketStatus":"Not Yet Opened","change":-0.08,"latestTime":"02-11 16:12:00 AEDT","open":13.6,"high":13.655,"low":13.1,"amount":3730645,"amplitude":0.041081,"askPrice":13.5,"askSize":74,"bidPrice":13.11,"bidSize":8213,"shortable":3,"etf":0,"ttmEps":1.147709,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":13.51,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.393064,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"41.13%","roe":"54.96%","lyrEps":1.086099,"volumeRatio":0.393064,"shares":126639526,"dividePrice":0,"high":13.655,"amplitude":0.041081,"preClose":13.51,"low":13.1,"week52Low":8.61,"pbRate":"5.26","psRate":"7.77","week52High":22.985,"institutionHeld":0,"latestPrice":13.43,"committee":0.982141,"eps":1.147709,"divideRate":0,"volume":280467,"delay":0,"ttmEps":1.147709,"open":13.6,"prevYearClose":18.61,"prevWeekClose":12.52,"prevMonthClose":16.69,"prevQuarterClose":18.61,"fiveDayClose":14.63,"twentyDayClose":19.3,"sixtyDayClose":18.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610983756","title":"Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610983756","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610983756?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:47","pubTimestamp":1770792440,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  disclosed a new on-market share buy-back program with a period of up to 12 months, which will be conducted under section 65 of the New Zealand Companies Act 1993 and will not exceed 5% of the total shares on issue 12 months before the commencement of the buy-back, according to a Wednesday Australian bourse filing.\"The board views the current share price as materially undervaluing Neuren's assets, relative to internal analyses and the range of recently published analyst valuations,\" said Chair Patrick Davies.Shares purchased under the buy-back will be cancelled upon acquisition, reducing the number of shares on issue, and the number of shares purchased under the buy-back will be less than the \"10/12\" limit prescribed in the Australian Corporations Act and will not require shareholder approval, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2610988807","title":"Neuren Pharmaceuticals -  Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2610988807","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610988807?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:00","pubTimestamp":1770789635,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2609384536","title":"Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609384536","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609384536?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:13","pubTimestamp":1770336816,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  facing regulatory uncertainty in the European Union  for its investigational drug trofinetide to treat Rett syndrome may delay royalties from sales in the region, Jefferies said in a note on Thursday.The European Medicines Agency  Committee for Medicinal Products for Human Use  gave a negative trend vote this week on the drug candidate's market authorization application, possibly due to concerns about the effect size in the confirmatory trial.Jefferies said the negative trend vote is an early indication that the regulatory authority might issue a negative opinion on the application at the final vote.The investment firm now expects royalties from EU sales of trofinetide to kick in the fourth quarter of fiscal 2026, and not second quarter.Meanwhile, it projects Neuren's experimental drug NNZ-2591 for treating Pitt-Hopkins Syndrome, a rare neurodevelopmental disorder, will receive reimbursement approval in the US in fiscal 2029.Jefferies lowered the company's fisca","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHMP","BK7508","EMA","EMA.AU","BK4087","BK7129","BK4156","NEU.AU","BK4081","BK7096"],"gpt_icon":0},{"id":"2609533926","title":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533926","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533926?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:39","pubTimestamp":1770334764,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cutsUpdates** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses** St","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL6N3Z11HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JEF","ACAD","BK7096","LU2065170008.USD","LU2065171402.SGD","BK4127","BK7508","LU2065171311.SGD","BK4559","LU2065169927.USD","NEU.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":15,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.049129}]}}